ROCKVILLE, Md., Sept. 11, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Karl Johe, PhD, will give an update on the NSI-189 ongoing clinical trial in major depressive disorder (MDD) at the 6 th Neurodegenerative Conditions Research and Development conference, September 13-14, in San Francisco, CA ( http://www.gtcbio.com/index.php?option=com_conference&file=speaker&cn=5th%20Neurodegenerative&cid=37). NSI-189 is the lead compound in Neuralstem's neurogenic small molecule platform, which seeks to develop oral drugs for CNS conditions, such as depression and chronic traumatic encephalopathy (CTE). Dr. Johe's talk, " Novel Neurogenic Drugs Targeting Hippocampal Degeneration," will take place on September 14th at 11:10 AM PDT. Dr. Johe is the Chairman and Chief Scientific Officer of Neuralstem. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "We are pleased with the progress of NSI-189 in the trial for major depression, which has progressed from healthy volunteers to MDD patients," said Dr. Johe. "Evident from recent findings in Alzheimer's disease research, neurodegeneration occurs two decades before the first symptom is apparent. We should consider MDD as a neurodegenerative disease. By recruiting the endogenous neural stem cells in the patient's brain, NSI-189, a one a day oral drug, aims to counter the chronic neurodegeneration, stimulate the generation of new neurons in hippocampus, and increase hippocampal volume. The drug should also work on other diseases such as Alzheimer's dementia that involve progressive neurodegeneration and eventual atrophy of hippocampus." About Neuralstem Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA. In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.